Outlook Therapeutics (OTLK) stock plunged 27% pre-market after announcing a proposed stock offering of undisclosed size. The company aims to use the proceeds for working capital. This follows recent debt financing and an earlier FDA rejection of its wet AMD treatment, ONS-5010.